AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (3 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Systematic Review | Open Access

Adjunctive Anweiyang capsules combined with Western medicine for peptic ulcer disease: a systematic review and meta-analysis of randomized controlled trials

Hong-san Zhang1,§Zhi-jun Bu2,3,§Yuan Sun4,5Shi-yu Tian1Yuan-hang Zhao1Kang Han1Zhao-lan Liu4Hui-lan Liu6( )
Department of Pediatrics, Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing, 100029, China
Department of Colorectal Surgery, Jiangsu Province Hospital of Chinese Medicine, Nanjing, 210029, China
Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, 210023, China
Center for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China
Yantai Center for Disease Control and Prevention, Yantai, 264003, China
Scientific Research Department, Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing, 100029, China

§These authors contributed equally to this work.

Show Author Information

Abstract

Introduction

Anweiyang capsules, a Chinese patent medicine, are used to reinforce qi, resolve toxic substances, and promote healing. In this study, we aimed to conduct the first meta-analysis comprehensively evaluating the clinical effectiveness and safety of Anweiyang capsules combined with Western medicine for the treatment of peptic ulcer disease (PUD).

Methods

Eight databases were systematically searched up to July 2025 and the further updated to May 1, 2026. The Cochrane risk of bias (ROB) 2.0 tool was used to assess the risk of bias in the included randomized controlled trials (RCTs), and evidence quality was evaluated using the GRADE tool.

Results

Thirty-six RCTs involving 3858 patients were included. In subgroup meta-analyses based on the background Western medicine regimen, the addition of Anweiyang capsules was associated with a higher clinical effectiveness rate compared with Western medicine alone (standard quadruple therapy: risk ratio [RR] = 1.19, 95% confidence interval [CI]: 1.13, 1.24; standard triple therapy: RR = 1.11, 95% CI: 1.06, 1.16; other regimens: RR = 1.20, 95% CI: 1.16, 1.25). Similar associations were observed for Helicobacter pylori eradication (quadruple: RR = 1.24, 95% CI: 1.17, 1.31; triple: RR = 1.16, 95% CI: 1.10, 1.23; and other: RR = 1.20, 95% CI: 1.13, 1.27). Owing to heterogeneity, gastrointestinal hormones, cytokines, and angiogenic markers were analyzed descriptively, demonstrating reductions in gastrin, motilin, and interleukin-6, along with increased vascular endothelial growth factor levels. Traditional Chinese medicine treatment was also associated with reductions in epigastric pain scores and peptic ulcer recurrence rates. No significant differences in adverse events were observed between the groups. However, most studies showed “some concerns” regarding risk of bias based on ROB 2.0 and low GRADE evidence quality.

Conclusion

Although this study suggests Anweiyang capsules combined with Western medicine is effective and safe for PUD, further high-quality, large-scale RCTs are warranted for confirmation.

Registration:

The study protocol was registered with the International Prospective Register of Systematic Reviews (https://www.crd.york.ac.uk/PROSPERO/, CRD420251087273).

Electronic Supplementary Material

Download File(s)
Appendix 1.docx (29.7 KB)
Appendix 2.xlsx (11 KB)

References

【1】
【1】
 
 
Evidence-Based Chinese Medicine and Technology Assessment
Article number: 9570034

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Zhang H-s, Bu Z-j, Sun Y, et al. Adjunctive Anweiyang capsules combined with Western medicine for peptic ulcer disease: a systematic review and meta-analysis of randomized controlled trials. Evidence-Based Chinese Medicine and Technology Assessment, 2026, 2(2): 9570034. https://doi.org/10.26599/eCMTA.2026.9570034

565

Views

24

Downloads

0

Crossref

Received: 20 March 2026
Revised: 16 April 2026
Accepted: 22 May 2026
Published: 18 June 2026
© 2026 Beijing University of Chinese Medicine. Production and hosting by Tsinghua University Press.

This is an open access article under the CC-BY license (http://creativecommons.org/licenses/by/4.0/).